Home Business & Economics

Business & Economics

European Union Accepts New Marketing Application for Biosimilar Formulation of Trastuzumab...

The European Medicines Agency (EMA) has validated and accepted trastuzumab biosimilar HD201 (Tuznue®) for review the Marketing Authorization Application (MAA). The...

Arfolitixorin Receives Clinical Patent Approval in the United States

Arfolitixorin, a proprietary drug candidate being developed by clinical stage biotech company Isofol Medical to increase the efficacy of standard of care...

Using a Simple Blood Test Helps Detecting Cancer Earlier Than Ever...

Tumor biopsies represent the standard for cancer diagnosis. They are the primary method for molecular testing designed to guide the...

United States Patent and Trademark Office Issues Patents to Oncoceutics

Earlier this month Oncoceutics confirmed that the United States Patent and Trademark Office (USPTO) has issued patent to the company with an...

Phase I/IIa Trial Shows 58% Overall Response Rate in mCRC Patients...

The open-label extension Phase I/IIa clinical trial, ISO-CC-005, investigates arfolitixorin (Modufolin; MTHF; Isofol Medical) as part of the first-line treatment regimen...

Natera Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

One of the leaders in cell-free DNA testing, Natera, a worldwide genetic testing and diagnostics company that’s changing how doctors and patients...

Sun Pharma Launches Novel, Premixed, Ready-to-Infuse Formulation of Gemcitabine ...

Sun Pharma, a global specialty generic company based in Mumbai, India, which provides innovative, high-quality, affordable medicines trusted by physicians and patients...

New Approach May help Control Urinary Incontinence Following Prostate Cancer Surgery

Local therapy for prostate cancer may includes radical prostatectomy and radiotherapy. Both therapies share a complication of urinary incontinence. These...

Three Recommendations to Better Understand HIPAA Compliance

According to the United States Department of Health and Human Services, approximately 70% of organizations are not HIPAA Compliant. 

Daiichi Sankyo Accelerates Biologics License Application for Trastuzumab Deruxtecan

Japaneses drug-maker Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and ...

LATEST